THE National Agency for Food and Drug Administration and Control (NAFDAC) issued a public health warning on Thursday evening regarding the circulation of a “counterfeit” malaria medication.
The drug, Combiart Dispersible Tablets (20/120 mg), “is manufactured by Strides Arcolab Limited, based in India. The product was discovered in FCT and Rivers State during surveillance activities,” NAFDAC said in a series of posts on X.
Strides Arcolab Limited has not reacted to the development.
The drug contains zero active ingredients, rendering it ineffective in treating malaria, NAFDAC added.
Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected mosquitoes, according to WHO.
The drug agency said the registration number on the drug packet was “incorrect” and that the drugs were manufactured between February and June 2023.
“Healthcare professionals and consumers are advised to report any suspicion of the sale of substandard and falsified medicines or medical devices to the nearest NAFDAC office,” NAFDAC urged on X.
The agency stressed the drug lacks proper quality control, potentially leading to serious health consequences.
The drug also fails to effectively treat illnesses like malaria, allowing the disease to worsen, NAFDAC warned.
Trending
- FG makes U-turn, withdraws Dakingari’s appointment as Turkey ambassador-designate
- US urges Nigeria to intensify protection of Christian communities
- Davido’s father breaks silence, insists DNA tests prove no paternity
- Netanyahu joins Trump’s ‘board of peace’ despite earlier objections
- FULL LIST: Names of 177 Kaduna abducted worshippers
- Kaduna: Police make U-turn, confirm abduction of over 100 churchgoers
- Court throws out Anyanwu’s suit seeking recognition as PDP national secretary
- UK Liberal Democrats leader Davey slams Trump’s Greenland bid as ‘gangster’ tactics
- Court adjourns trial of driver in Anthony Joshua crash to Feb 25
- Ex-Nigeria minister Alison-Madueke appears in London court for ‘£100,000 bribery’ trial

